- Home
- LDI vs IOVA Comparison
LDI vs IOVA Comparison
Compare LDI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- IOVA
- Stock Information
- Founded
- LDI 2010
- IOVA 2007
- Country
- LDI United States
- IOVA United States
- Employees
- LDI N/A
- IOVA N/A
- Industry
- LDI Finance: Consumer Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDI Finance
- IOVA Health Care
- Exchange
- LDI Nasdaq
- IOVA Nasdaq
- Market Cap
- LDI 894.0M
- IOVA 975.1M
- IPO Year
- LDI 2021
- IOVA N/A
- Fundamental
- Price
- LDI $4.28
- IOVA $2.27
- Analyst Decision
- LDI Sell
- IOVA Buy
- Analyst Count
- LDI 3
- IOVA 11
- Target Price
- LDI $2.30
- IOVA $11.90
- AVG Volume (30 Days)
- LDI 10.8M
- IOVA 11.1M
- Earning Date
- LDI 11-04-2025
- IOVA 11-06-2025
- Dividend Yield
- LDI N/A
- IOVA N/A
- EPS Growth
- LDI N/A
- IOVA N/A
- EPS
- LDI N/A
- IOVA N/A
- Revenue
- LDI $1,124,074,000.00
- IOVA $241,525,000.00
- Revenue This Year
- LDI $21.95
- IOVA $67.40
- Revenue Next Year
- LDI $15.72
- IOVA $56.32
- P/E Ratio
- LDI N/A
- IOVA N/A
- Revenue Growth
- LDI 27.06
- IOVA 636.99
- 52 Week Low
- LDI $1.01
- IOVA $1.64
- 52 Week High
- LDI $4.51
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- LDI 78.59
- IOVA 45.40
- Support Level
- LDI $3.01
- IOVA $2.27
- Resistance Level
- LDI $4.03
- IOVA $2.46
- Average True Range (ATR)
- LDI 0.36
- IOVA 0.15
- MACD
- LDI 0.22
- IOVA -0.00
- Stochastic Oscillator
- LDI 90.82
- IOVA 29.09
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.